TICKERNERD
Menu
XRAYXRAYHealthcare · Medical Instruments & Supplies

XRAY Stock Forecast: Dentsply Sirona, Inc. Price Predictions for 2026-2027

Last close, 27 Oct 2026
$9.35
+1.41% on the day

The 17 Wall Street analysts covering Dentsply Sirona, Inc. hold a median 12-month price target of $12 — +28.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 26 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.8B
Ticker Nerd rank
86/ 100
Median analyst target
$12
Analysts covering
17
Revenue$898.0M−4.1% y/y
Operating income$83.0M
Net income$36.0M
Free cash flow$55.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.4%
1M
−0.5%
YTD
−18.2%
1Y
−27.6%
From 52W high
−36.3%
From 52W low
+11.0%
$8
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XRAY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dentsply Sirona, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 26 Oct 2026
86/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Issuance
95
Accruals
93
Volatility
87
Growth
68
Quality
59
Revisions
49
Size
36
Momentum
32

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (32): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XRAY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XRAY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$8$10$12$14$16$18Jan 26Apr 26Jul 26Oct 26XRAYHigh $17Median $12Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
4 Buy12 Hold1 Sell
Low $9Median $12High $17

The green dot is the last close — the median target sits +28.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
26 Oct 2026Barrington ResearchMaintainsOutperform$15 → $13
22 Oct 2026MizuhoMaintainsNeutral$14 → $12
14 Oct 2026Leerink PartnersMaintainsMarket Perform$14 → $10
14 Oct 2026Leerink PartnersMaintainsMarket Perform—
9 Oct 2026Piper SandlerMaintainsNeutral—
9 Oct 2026Piper SandlerMaintainsNeutral$14 → $12
17 Sept 2026BMO CapitalMaintainsMarket Perform$13 → $10
17 Sept 2026BMO CapitalMaintainsMarket Perform—
24 Aug 2026BarclaysMaintainsUnderweight$9.00 → $11
24 Aug 2026BarclaysMaintainsUnderweight—
29 July 2026Piper SandlerMaintainsNeutral$13 → $14
29 July 2026Piper SandlerMaintainsNeutral—
9 July 2026BMO CapitalInitiatesMarket Perform—
4 June 2026BarclaysMaintainsUnderweight—
7 May 2026UBSMaintainsBuy—
6 May 2026MizuhoMaintainsNeutral—
15 Apr 2026CitigroupInitiatesSell—
2 Mar 2026Barrington ResearchMaintainsOutperform—
2 Mar 2026MizuhoMaintainsNeutral—
27 Feb 2026BairdMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XRAY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

XRAY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 27 Oct 2026, Dentsply Sirona, Inc. returned −27.6% against +13.5% for the S&P 500, dividends included.

XRAY vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26XRAYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XRAY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.2%
Analysts raising
0
Analysts cutting
3
Fundamentals

Dentsply Sirona, Inc. (XRAY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 88% of US stocks

Price / sales
0.5×

Cheaper than 80% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
7.5×

Cheaper than 47% of US stocks

Growth & margins
Revenue growth (YoY)
−4.1%

Higher than 21% of US stocks

Earnings growth (YoY)
−4.1%

Higher than 32% of US stocks

Gross margin
54.9%

Higher than 68% of US stocks

Operating margin
9.2%

Higher than 63% of US stocks

Net margin
−15.0%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−33.0%

Higher than 26% of US stocks

Return on assets
2.0%

Higher than 58% of US stocks

Dividend yield
6.9%

Higher than 95% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Dentsply Sirona, Inc. (XRAY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dentsply Sirona, Inc. has a market value of $1.8B and an enterprise value of $3.9B.

  • Revenue in the twelve months to 30 June 2026: $3.6B. The latest quarter shrank 4.1% year on year.

  • Net income over the same four quarters: −$547.0M, a −15.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.75.

  • Free cash flow in the twelve months to 30 June 2026: $143.0M, after $176.0M of capital spending.

  • Dentsply Sirona, Inc. spent $96.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 199.2M.

  • Trailing P/E: −3.1×; forward P/E: 6.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 6.95%, paying out 30% of earnings.

  • Dentsply Sirona, Inc. employs 14,000 people — $260K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 27 Oct 2026

Data provided by Twelve Data

Peers

XRAY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
XRAYDentsply Sirona, Inc.$1.8B86
BLFSBioLife Solutions, Inc.$1.9B—
LMATLeMaitre Vascular, Inc.$1.9B80
AZTAAzenta, Inc.$1.7B81
KMTSKestra Medical Technologies Ltd.$1.7B26
STAASTAAR Surgical Co.$1.2B73
ATRCAtriCure, Inc.$3.1B96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dentsply Sirona, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XRAY news & analysis

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 27 Oct 2026negative

PRNewsWire reports a law firm is encouraging Dentsply Sirona shareholders to contact it to discuss their rights and options regarding alleged insider breaches of fiduciary duties. The firm says there is no cost or obligation to discuss the matter and that it would work on a contingent-fee basis.

Why it matters — The notice raises a potential governance concern involving Dentsply Sirona insiders that may be relevant to XRAY shareholders.

Dentsply Sirona to Host Third Quarter 2026 Conference Call on November 5

GlobeNewsWire · 20 Oct 2026neutral

Dentsply Sirona announced it will host a conference call and live webcast on November 5, 2026, at 4:30 p.m. EST, to review third-quarter 2026 financial results. Earnings materials will be posted on the company’s investor website before the call.

Why it matters — XRAY watchers can note when the company will discuss its quarterly results and where related materials will be available.

Dentsply Sirona Expands U.S. Digital Dentistry Reach With Midwest Deal

Zacks Investment Research · 12 Oct 2026positive

Dentsply Sirona is expanding its U.S. distribution reach through Midwest Dental. The deal is aimed at boosting digital dentistry adoption and broadening access to its technology portfolio.

Why it matters — XRAY watchers may note the deal’s focus on widening access to the company’s digital dentistry technology in the U.S.

Dentsply Sirona Continues North American Commercial Expansion with Midwest Dental Agreement

GlobeNewsWire · 6 Oct 2026positive

Dentsply Sirona expanded its relationship with Midwest Dental. The agreement builds on other agreements announced this year to strengthen its North American dealer network and broaden customer access to its products and technology.

Why it matters — XRAY watchers may note the agreement as part of the company’s ongoing efforts to expand its North American distribution reach.

FAQ

Frequently asked questions about XRAY stock

What is the XRAY stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Dentsply Sirona, Inc. have a median 12-month price target of $12, with estimates ranging from $9 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XRAY stock a buy right now?

Of the 17 analysts covering Dentsply Sirona, Inc., 4 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Dentsply Sirona, Inc. 86 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XRAY?

As at 26 Oct 2026, Dentsply Sirona, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will XRAY stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +28.3% from the last close, and Ticker Nerd's factor model ranks Dentsply Sirona, Inc. 86 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XRAY stock forecast for 2030?

No analyst covering Dentsply Sirona, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XRAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $17 over the next 12 months.

How has XRAY stock performed over the past year?

Dentsply Sirona, Inc. returned -27.6% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dentsply Sirona, Inc. do?

Dentsply Sirona Inc. is a global dental products and technologies company that serves dental practices, clinics, laboratories, and distributors worldwide.

What is the latest news on XRAY?

The most recent item we track (PRNewsWire, 27 Oct 2026): "Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?". PRNewsWire reports a law firm is encouraging Dentsply Sirona shareholders to contact it to discuss their rights and options regarding alleged insider breaches of fiduciary duties. The firm says there is no cost or obligation to discuss the matter and that it would work on a contingent-fee basis.

Company

About Dentsply Sirona, Inc.

Dentsply Sirona Inc. is a global dental products and technologies company that serves dental practices, clinics, laboratories, and distributors worldwide. The company develops, manufactures, and markets a broad portfolio that includes dental consumables, restorative materials, digital imaging systems, CAD/CAM restoration platforms, treatment centers, handpieces, hygiene systems, orthodontic and implant products, and specialty solutions for endodontics and other oral care applications. Dentsply Sirona also provides workflow-oriented technologies designed to support diagnosis, treatment planning, and chairside procedures across modern dental settings. Headquartered in Charlotte, North Carolina, Dentsply Sirona is a major supplier in the professional dental market, combining equipment, software-enabled tools, and everyday consumables to support clinical efficiency and patient care.

CEO Mr. Daniel T. Scavilla · 14,000 employees · United States · https://www.dentsplysirona.com